On Tuesday, June 10, the Senate Appropriations Subcommittee on Labor, Health & Human Services (LHHS) earmarked an additional $100 million for Alzheimer's research in their 2015 fiscal year funding bill.
Cure Alzheimer's Fund is gratified that President Obama has specifically highlighted Alzheimer's disease research to benefit from increased research funding included in the Administration's Fiscal Year 2015 budget proposal.
Washington (November 7, 2013) – As the country commemorates November as National Alzheimer’s Awareness month, Senator Edward J. Markey (D-Mass.) has been announced as the new Senate co-chair of the Bipartisan Congressional Task Force on Alzheimer’s Disease. Senator Markey was co-chair of the Task Force with Rep. Chris Smith (R-N.J.) when he served in the House of Representatives. While in the House, then-Rep. Markey co-authored the National Alzheimer’s Project Act, which mandated the development of a first-ever comprehensive National Plan to Address Alzheimer’s Disease.
The President states in the budget message for the National Institutes of Health that the proposed budget delivers on the "... Administration's commitment to enhance investment in Alzheimer's research" by adding approximately $80 million to the current year’s amount. This commitment which moves Alzheimer’s research from about 1.6% of the NIH budget to about 1.8% includes, "... investments in basic research on the fundamental causes and mechanisms of disease ..."
Cure Alzheimer’s Fund is grateful to President Obama for the Administration’s continued commitment to curing Alzheimer’s disease. With the implementation of the first ever National Plan To End Alzheimer’s Disease, to which Cure Alzheimer’s Fund was a contributor, and his specific targeting of the disease last night in the State of the Union address, President Obama has highlighted a national resolve to defeat this disease.
A new study by David Holtzman of Cure Alzheimer’s Fund’s Research Consortium published by the journal “Science Translational Medicine” brings sharp new focus on the direct relationship between the accumulation of Abeta in the brain and notorious sleep problems associated with Alzheimer's disease. This NIH-funded study (also supported by Ellison Medical Foundation) was made possible by early pilot studies initiated by the Cure Alzheimer's Fund --- another great example of leveraging innovative research ideas into substantially funded, high impact projects.
UC San Diego neuroscientist Steve Wagner, a previous recipient of two substantial grants from Cure Alzheimer’s Fund (CAF), has been awarded a $1 million NIH “Blueprint” grant for the fast-track development of a promising Alzheimer’s drug therapy.
“This is further validation of our venture model,” says CAF President and CEO Tim Armour. “We’ve always been willing to take considerable risk for the prospect of faster progress. Steve’s project is a sterling example of why our founders adopted this strategy. Thanks in part to CAF’s support for Wagner’s research, the world is now much closer to a promising new class of Alzheimer’s drugs.”